Reviewed product and indication
Use current labeling and licensed professional guidance. Approval is product- and indication-specific.
Peptide education, properly labeled
Understand peptides without confusing research, prescriptions, and marketing.
Clear status labels. Primary sources. Practical explanations of evidence, quality claims, approval, and uncertainty—without generic dosing protocols or sales hype.
Source-linkedStatus-labeledCommercially transparentUpdated as evidence changes
The right first question
What kind of peptide information are you looking at?
The same ingredient name can appear in four very different contexts. Start by identifying the category.
Not FDA-approved
May be prepared under limited legal pathways, but it is not reviewed like an approved drug or generic.
Still in clinical development
A trial result is not a product approval or a personal-use protocol.
Laboratory context
A disclaimer does not establish sterility, identity, potency, safety, or suitability for human use.
How this site works
Evidence first. Affiliate links later.
HowToUsePeptides.net is the authority site. It does not sell products or process transactions. Future links may point to a separate seller, but commercial relationships will never erase approval status, evidence limits, or visible disclosures.
- Primary regulatory and clinical sources
- Clear separation of human, animal, and laboratory evidence
- No anonymous “medical review” badges
- No generic injection or reconstitution protocols
Peptide Library
Status pages that tell you what is known—and what is not.
Ipamorelin
Ipamorelin status, growth-hormone secretagogue claims, FDA concerns, stacking uncertainty, and limitations of online protocols.
View evidence profile →GHK-Cu
How topical cosmetic discussion differs from injectable use, plus FDA safety concerns, evidence limits, and product-quality questions.
View evidence profile →TB-500
Regulatory status, evidence limitations, identity confusion, quality questions, and safety uncertainty surrounding TB-500.
View evidence profile →BPC-157
BPC-157 evidence, regulatory status, human-data limitations, safety questions, and the difference between research interest and established treatment.
View evidence profile →Retatrutide
Current investigational status, trial context, online-product risks, and why retatrutide sold by research vendors is not clinical-trial material.
View evidence profile →Tesamorelin
What tesamorelin is approved for, what the label does not establish, formulation differences, and why broad weight-loss claims need scrutiny.
View evidence profile →Quality claims decoded
“99% pure” is not a complete safety statement.
Learn the difference between identity, chromatographic purity, assay, sterility, endotoxin, fill weight, and batch traceability.
Latest resources
Research, regulation, and practical interpretation
Peptide Content Safety Checklist for Readers
A reader-focused checklist for spotting missing disclosures, unsupported claims, and potentially dangerous instruction content.
Read guide →FDA Approval Applies to Products, Not Just Ingredient Names
Why an approved active ingredient does not make every compounded vial, salt form, or research product FDA-approved.
Read guide →Clinical Trial Phases for Peptide Research
What phase 1, 2, 3, and post-approval studies can\u2014and cannot\u2014tell you about a peptide candidate.
Read guide →